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The use of the randomised consent design (commonly known as the Zelen design) is a 
controversial issue in randomised controlled trials. In the Zelen design, participants are randomly 
allocated prior to seeking consent. Those participants allocated to the intervention group are then 
approached and offered the intervention, which they can decline or accept.  
Zelen first proposed the design in 1979. It has been infrequently used since this time although 
there are some notable exceptions in nursing, midwifery and some medical specialties. 
Aim 
This paper describes the Zelen design, including the two forms used (the single and double 
consent versions) and discusses the advantages and disadvantages of using such a design.  
Method 
An explanation of the differences between the Zelen design and a conventional randomised 
controlled trial is presented. In a conventional design, detailed knowledge of the alternative 
interventions is given to the prospective participant. The participant gives consent and is allocated 
to one of the groups. In a Zelen design, participants are randomly allocated and then approached 
and offered the group to which they were allocated. The Zelen design is used firstly, to reduce 
disappointment bias in the conventional consent-randomisation process and secondly, to remove 
subjective bias in the recruitment process.  
There are concerns relating to the use of the Zelen design. These include ethical concerns 
relating to the timing of random allocation and consent and the collection of clinical data. 
Conclusion 
It is hoped that by presenting issues pertaining to the Zelen design, other nursing and midwifery 
researchers may be prompted to consider its use when designing clinical research. The Zelen 
design is controversial and debate on the merits and shortcomings is useful. This paper 
contributes to the ongoing debate.  
 
Key words: Randomised controlled trial, research design, research methodology, consent, clinical 
research, nursing, midwifery. 
3 
Introduction 
The randomised consent design was proposed by Marvin Zelen in 1979. In the randomised 
consent design, participants are randomly allocated prior to seeking consent. Those participants 
allocated to the intervention group are then approached and offered the intervention, which they 
can decline or accept. The randomised consent design is also known as pre-randomisation 
design and post-randomisation design (Snowden et al. 1998). In this paper it is known as the 
‘Zelen’ design.  
The Zelen design has not been widely used in nursing research, although there are some notable 
exceptions (Cherkin et al. 1996; Steiner et al. 2001). We have recently used the Zelen design in a 
randomised controlled trial of a new model of midwifery care in Australia (Homer et al. 2000; 
Homer et al. 2001a; Homer et al. 2001b). In both designing our trial and submitting for 
publication, we were subjected to many of the debates and controversies surrounding the use of 
the Zelen design. These are presented in this paper to help clarify many of the issues and to help 
others who may be considering using a Zelen design.  
Conventional design 
The Zelen design (1979) provides an alternative sequence in the randomisation-consent process, 
with randomisation preceding consent. In conventional designs, prospective participants are 
identified, approached and asked to provide consent and are randomly allocated to (usually) one 
of two options (Figure 1).  
In a conventional design, detailed knowledge of the alternative interventions is given to the 
prospective participant. The participant gives consent and is allocated to one of the groups. 
Detailed knowledge of the study may influence the responses of participants in trials that 
measure outcomes reflecting feelings and opinions (Dennis 1997). For example, negative 
responses may reflect a control participant’s disappointment or dissatisfaction with their allocation 
to an experimental or control group, whereas positive responses may correspond to a treated 
participant’s apparent loyalty to the intervention. 
The effect of the consent-randomisation progression on outcomes has also been reported in 
other research where the unblinded nature of the trial leaves participants, who are not randomly 
allocated to their treatment of choice, feeling ‘disappointed and demoralised’ (Bradley 1993). For 
example, trials in Holland testing the therapeutic effectiveness of heroin provision have reported 
that participants allocated to the control group have been disappointed and this has affected the 
trial results. Disappointment also led to large scale withdrawals from the study and adversely 
affected the validity of the trial (Schellings et al. 1999; Hartnoll et al. 1980). 
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These examples demonstrate that the use of a conventional design can mean some trials 
produce misleading results. Other factors also influence the results, particularly the extent to 
which they can be generalised to a larger population. The next section will discuss selection bias, 
which can mean an unrepresentative sample is recruited. 
Factors that influence recruiting a representative sample 
The system of recruitment-consent-randomisation followed in conventional designs appears to be 
objective. In reality, objectivity may not always occur and selection bias may result. Personal 
experience suggests that clinicians (midwives, nurses and doctors) sometimes make personal or 
professional judgements about which participants researchers can access for recruitment and 
consent. An inability to speak English, perceived low intelligence and social or emotional 
problems may be used as spurious reasons to keep potential participants away from researchers. 
Clinicians might also have their own opinions on the merits of the research. This may mean that 
they are reluctant for ‘their’ patients to be included and deny people the capacity to decide for 
themselves.  
Busy, understaffed outpatient clinics may also contribute to the introduction of bias as the 
potential sample is reduced. Clinicians may lack the time to refer participants to researchers. The 
sense of anxiety that is often felt in these busy areas means the pressure to move people through 
the system, without further delay, is high. These processes are usually subtle and clinicians and 
researchers may be unaware they are occurring. Nonetheless, they may mean participants are 
removed from the sample.  
Personal experience suggests that researchers can also make idiosyncratic judgements about 
which potential participants are approached. Certain types of people, for example, English 
speaking participants who are articulate, friendly or affable may be perceived by the researcher 
as being more likely to participate and therefore are more likely to be approached. Frequent 
refusal is an unpleasant experience. Therefore researchers may be more inclined to approach 
those participants who they perceive are more likely to participate. A rigorous, systematic protocol 
to ensure that all eligible people are approached in a fair and equitable manner is important to 
reduce this form of bias. 
Socio-economic status also seems to influence recruitment and participation. Zelen (1979) 
suggested that researchers are more likely to approach people from high and low socio-economic 
groups rather than people from the middle ranges of socio-economic status. People of high socio-
economic status are more likely to be approached because their clinicians believe they will 
understand the research and give consent. In contrast, people of low socio-economic status are 
often approached as it is felt that they will leave the decision up to the doctor. This phenomenon 
will affect the characteristics of the eventual sample. 
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The type of trial also seems to influence the type of participants who are recruited. People who 
consent to large prevention trials seem to be better educated, from a higher socio-economic 
strata, married, employed and greater users of preventative care and other medical services 
(Hunninghake 1987; Hunninghake et al. 1987) Conversely, more privileged and better educated 
individuals are discouraged from participating in some treatment trials (Thong & Harth 1991). This 
means a person’s characteristics influence their likelihood of being recruited. The generalisability 
of results from such trials may therefore be questionable unless recruiting protocols are rigorous. 
The factors identified may bias results in a randomised controlled trial. The Zelen design may be 
able to reduce some of the biases related to use of the conventional progression of consent-
randomisation. The Zelen design is discussed in the next section. 
The Zelen design 
In a Zelen design, participants are identified and random allocation takes place before consent is 
sought for the intervention. There are two versions of the Zelen design: ‘single consent’ and 
‘double consent’ (Zelen 1979; 1990) In both versions, the allocations are concealed, that is, 
researchers are unaware as to the next allocation. 
In the single consent version, participants allocated to the control group are not asked for 
consent, they receive standard treatment without mention of the trial. Participants allocated to the 
experimental group are asked whether they consent to the new treatment. If they decline they 
receive the standard treatment. All randomly allocated participants are included in the analysis, 
whether they consented or not (Figure 2).  
The double consent version differs as participants allocated to the control group are asked for 
their consent to the standard treatment and those who decline may receive the experimental (or 
some other) treatment. Participants allocated to the experimental group are asked whether they 
consent to the new treatment. If they decline they receive the standard treatment as in the single 
consent version (Figure 3). 
The single consent version is suitable when the experimental treatment is only available within 
the confines of the trial and is being compared to standard care. The double consent version is 
suitable when the experimental treatment is available outside the trial, or when two ‘standard’ 
treatments are compared.  
In both versions the clinician and researchers know who is to be approached for consent. An 
assessment of outcome can however be made blind to allocation. 
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Use of a Zelen design 
The Zelen design appears to have been used infrequently since it was first proposed more than 
20 years ago. Only a few trials are reported in the literature. Most have been in the field of 
cancer, (Fisher et al. 1985; Moertel et al. 1984) with a few examples from neonatalology (Bartlett 
et al. 1985; O'Rourke et al. 1989) and osteoarthritis (Chang et al. 1990). Three trials of continuity 
of midwifery care ( Homer et al 2001a; MacVicar et al. 1993; Flint et al. 1989) and two trials of 
continuous support during labour (Hemminki et al. 1990; Cogan & Spinnato 1988) have also used 
the Zelen design. There are two recent examples in nursing, a trial of nurse-led care in an acute 
service (Steiner et al. 2001) and a trial of patient education for back pain (Cherkin et al. 1996). 
The design has also been used in two small studies of extracorporeal membrane oxygenation in 
newborns babies (O'Rourke et al. 1989; Bartlett et al. 1985) It was thought to be unethical in 
these studies to discuss a potentially life saving treatment with parents and then withhold the 
treatment because the patient was allocated to the control group.  
More recently, a trial used the Zelen design to test the physical, social and psychological effect of 
contact with a stroke family care worker (Dennis et al. 1997). Participants were randomly 
allocated prior to consent. Those allocated to the intervention group were approached and asked 
to consent to follow up. Dennis (1997) justified use of the Zelen design, writing:  
detailed knowledge of the trial and its exact purposes are likely to bias or influence 
results. Thus, responses may reflect a control subject’s disappointment or dissatisfaction 
with not receiving a potentially beneficial treatment or a treated patient’s appreciation or 
loyalty to those providing the treatment (p. 1077).  
The Zelen design is clearly advantageous in some research, as it seems to reduce the sense of 
disappointment that participants allocated to the control group express. Other advantages are 
also outlined in the following section. 
Advantages of a Zelen design 
Zelen designs have been found to be advantageous in trials that have compared operations for 
breast cancer where conventional designs are unpopular with participants and clinicians (Zelen 
1990). In surgical research, the design has been suggested as a means to overcome the difficulty 
recruiting participants who have a definite preference for one procedure over another (Stirrat et al. 
1992). Proponents of heroin provision trials in The Netherlands have indicated that the Zelen 
design would be the best choice for their research as it would result in less disappointment bias, 
fewer dropouts and would lead to more reliable results being obtained (Schellings et al. 1999). 
Schellings et al (1999) suggest that the design has wider applicability, particularly when the 
experimental intervention is highly attractive to potential participants and when the control group 
receive standard treatment.  
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In a conventional design, participants have a 50 per cent chance (in a one-to-one ratio) of being 
able to receive the intervention. In a Zelen design, when participants who have been randomly 
allocated to the intervention group are approached for consent, they know that they can receive 
the new treatment. The Zelen design is advantageous for the participant, as they know which 
treatment will be given before providing consent (Zelen 1979). The consent process is simplified 
and there is a greater likelihood of the participants having a better understanding of the 
intervention to which they are consenting. Researchers may be more certain that the participant 
is giving informed consent to the intervention. Knowing the intervention to which participants are 
randomly allocated to receive may also ease both information giving and decision making 
processes for the clinician and participant and may not compromise the patient-physician 
relationship. 
The Zelen design may also improve rates of accrual in trials in which recruitment is difficult, as 
the design is weighted to include those who might otherwise have refused (Snowden et al. 1998). 
Using a Zelen design may encourage greater diversity (for example, in socio-economic status, 
cultural background) in the sample as the potential subjective nature of recruitment is removed. 
In conventional trials, ideally, all consenting participants are included in an intention to treat 
analysis, whereas, in a Zelen design, all randomly allocated participants are included. The post-
randomisation loss in conventional designs when participants withdraw because they are 
allocated to the arm that they least desire, is another aspect that may be reduced with the Zelen 
design (Zelen 1992). While this may be a benefit of using the Zelen design, there are ethical 
implications to consider. These are addressed later in the paper.  
There may be an apparent loss of efficiency due to the expected refusal of a proportion of 
participants. For example, if 90 per cent of participants accept treatment, 81 participants would be 
needed in a conventional design as compared to 100 in a Zelen design. Zelen (1979) argues that 
“this loss in efficiency may be illusory” (p. 1244). Usually, only a proportion of eligible patients in 
an institution are approached and asked to participate in a trial. Using a Zelen design, more 
patients can be entered into the trial as face-to-face approaches and selection bias does not 
influence recruitment. The Zelen design may mean efficiency is improved over a conventional 
design.  
Criticisms of the Zelen design 
The main criticisms of the Zelen design include ethical concerns with the consent-randomisation 
process, its potential loss of statistical power and the routine collection of clinical data. 
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The process of obtaining informed consent 
The main reason for the rejection of the Zelen design appears to be because consent is not given 
for randomisation (Marquis & Huston 1994; Ellenberg 1992) In most research using a Zelen 
design consent is obtained post-randomisation.  
Informed consent has promoted much controversy in recent years, particularly in the British 
Medical Journal in response to the trial conducted by Dennis et al (1997). McLean (1997) 
cautioned against Zelen designs because of the risk of embarking down the ‘slippery slope’ away 
from one of the fundamental ethical principles, that being, respect for persons. McLean agreed 
that while no harm had come to the participants in the Dennis et al trial (1997), their agreement 
had been based on partial rather than full information and she felt that it was dangerous to 
believe that this was adequate. McLean (1997) also indicated that if certain types of research 
could not fulfill unequivocal scientific standards, it is doubtful whether they should be done in the 
first place. Dennis (1997) questions whether it is ethical to randomly allocate patients into trials, 
which because of a methodological weakness, cannot provide an answer to the main question 
(p.1077). 
In contrast, it has been suggested that fully informed consent for randomisation can be 
‘needlessly cruel’ for potential trial participants (Tobias & Souhami 1993). Tobias and Souhami 
(1993), who describe themselves as being committed to the value of clinical trials, believe that the 
process of obtaining consent is traumatic for patients at a time when sensitivity is paramount. 
They feel that the process can damage the patient’s trust in their relationship with their doctor and 
patients end up being more confused and uncertain about the best decision. There is also the 
psychological impact as the clinician enrolling the patient in the trial has to admit that they do not 
know whether the intervention will actually work, leading the patient to doubt the effectiveness 
and possibly reducing the potential benefit. These issues can lead to low recruitment and high 
dropout rates, particularly among participants who have given consent and are subsequently 
randomly allocated to the control group.  
It is possible that participants are better informed when consent is sought in a Zelen design. 
Participants are 100 per cent certain of the treatment they will receive in a Zelen design rather 
being 50 per cent certain in a conventional design. 
Loss of statistical power 
Some researchers reject the Zelen design claiming that, in general, a number of randomly 
allocated participants will refuse the intervention resulting in incompatibility of the groups (Matts & 
McHugh 1987; Anbar 1983; Ellenberg 1984) A loss of statistical power may also occur if a large 
proportion of participants randomly allocated to the intervention group decline to participate. It has 
been estimated that if the overall refusal rate is greater than 15 per cent, twice the number of 
9 
patients will have to be recruited (Ellenberg 1984). If the intervention is attractive or desirable, it is 
likely that this dilution effect will be minimal, as only a small proportion of participants will decline. 
For example, low refusal rates were seen in the trials of continuous support in labour and 
continuity of midwifery care (Homer et al. 2001a; MacVicar et al. 1993; Hemminki et al. 1990; 
Flint et al. 1989; Cogan & Spinnato 1988). Therefore, researchers need to have confidence that 
more than 85 per cent of participants randomly allocated to the intervention group will accept the 
allocation.  
Collection of clinical data 
The collection of clinical data from participants who decline to take part in the trial has also been 
reported as a concern with use of the Zelen design (Snowden et al. 1998). 
Clinical data are widely collected in health care institutions for review and quality control 
purposes. Data are also routinely forwarded to health departments and disease registries to 
enable state and national reporting of health outcomes. For example, the annual report 
Australia’s Mothers and Babies (Day et al. 1999) is based on routine data collected without 
consent of the participants involved. This report and others are used widely utilised to assess 
maternity services and health outcomes and planning new services, however, none of the 
250,000 women were asked for their consent for the collection and distribution of this information. 
One might suggest that these participants were actually involved in an ongoing trial, that is, a trial 
of the effectiveness of Australian maternity service provision.  
Many hospitals collect data on the clinical outcomes of their patients. Women are not asked 
permission for this collection. These data are mostly used for quality control purposes and peer-
review audits within maternity units. Maternity units that do not collect this information would be 
seen as having quality assurance practices below acceptable standards.  
Recent changes to legislation in Australia and elsewhere, including the United Kingdom (UK) may 
make the use of routinely collected clinical data more difficult to use for research purposes. In 
New South Wales, privacy legislation enacted in 1998 states that personal information can only 
be used “for the purpose for which it was collected, for a directly related purpose, for a purpose to 
which the individual has consented” (NSW Government 1998, Section 17). In the UK, the Data 
Protection Act (Acts of the UK Parliament 1998) indicates that personal data can only be 
processed for research purposes if they will not cause any damage or distress to the data 
subject. Conditions have been placed on the use of such data that may make the use of personal 
data in research situations more difficult without explicit consent. Both these examples 
demonstrate that increasingly there are more conditions associated with the use of personal data 
and researchers must be mindful of these issues when planning and designing their research. 
The Zelen design may pose additional challenges in relation to privacy legislation.  
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A Zelen design instead of a conventional design 
The process of choosing the most appropriate design has been addressed in research that was 
conducted in the United Kingdom (UK) as a part of the Extra Corporeal Membrane Oxygenation 
(ECMO) trial in severely ill neonates in the mid-1990’s (UK Collaborative Trial Group 1996). This 
trial recruited mature newborns with acute and potentially irreversible respiratory failure and 
randomly allocated them to either ECMO, a form of respiratory support that had little unbiased 
evidence as to its efficacy, or to conventional management utilising ventilator support. Parents 
were asked to consent to this trial when they were very distressed and anxious and were given 
little time to make their decision. Results of the trial indicated that infants who received ECMO 
were more likely to survive than those who received conventional management.  
A series of qualitative interviews with 37 parents of surviving infants some time later revealed 
startling confusion over the randomisation and consent process (Snowden et al. 1997). Many 
parents did not understand the nature of the trial, the process of random allocation or the need for 
this method of allocation.  
The researchers had initially proposed a Zelen design, however this was rejected after 
discussions with consumer group representatives. It was felt that the potential non-disclosure in a 
Zelen design was unethical and that those who were not informed would feel upset or angry that 
they were unwitting participants in a clinical trial. It is possible that the use of a Zelen design 
would have reduced the confusion relating to the process around randomisation for these 
parents. Zelen (1979) suggested that presenting potential participants with only one option 
reduces the, often difficult, decision-making process and the anxiety associated with the process 
of random allocation. Allmark (1999) a medical ethicist has suggested that the process of 
obtaining informed consent in the ECMO trial had the potential to cause harm, particularly by 
disappointing those who ended up in the control group. Others have argued that consent for a 
neonatal trial is not only difficult to obtain, it is unlikely to be fully informed because of the parents’ 
distress and the immediacy of the decision (Mason 1997). An editorial in The Lancet suggested 
that the Zelen design may be appropriate in these neonatal trials (Anonymous 1995). The 
opposing view is that parents have the right to decide how much information they receive and 
should therefore be able to make their own decision about participation (Meren 1995). 
Conscious of this ongoing debate about the potential usefulness of the Zelen design in the ECMO 
trial, Snowden et al (1998) conducted an additional qualitative study with the parents of 25 infants 
from the original trial. This study asked parents how they would have reacted to a Zelen design. 
The parents were evenly divided in accepting or rejecting the design, however those who rejected 
the design were more likely to be from the control group. It was apparent that Zelen 
randomisation would not necessarily minimize the stress for those who were allocated to the 
intervention group as the participants felt that they would still have to make an ‘impossible’ 
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decision. Some parents saw Zelen randomisation as a kinder approach, whereas others felt that 
the gathering of information as a coping strategy and access to information as a right (Snowden 
et al. 1998). It is possible that the results of this qualitative study might have been different if the 
parents were unaware of the results of the ECMO trial or if the results were reversed. It is 
possible that responses of the parents were mediated by the fact that ECMO infants were more 
likely to survive and that all parents interviewed were those of surviving infants. 
Conclusion 
This paper has discussed the reasons for the use of the Zelen design and presented some of the 
advantages and disadvantages of the design. The Zelen design provides one means to reduce 
systematic bias in clinical trials. It is helpful because maintains allocation concealment, potentially 
reduces subjective bias in the process of asking people to participate in trials and helps overcome 
the difficulty in recruiting people who have a definite preference for one intervention over another. 
It may also be useful in reducing disappointment bias, particularly in research where ‘satisfaction’ 
is an outcome.  
However, there are a number of concerns raised by the use of the design. These include the 
need to be certain that most participants will accept the intervention offered and few people will 
withdraw. The other main concern is that people are randomly allocated prior to giving consent. 
These issues need consideration in the planning of any trial considering use of the Zelen design.  
Nursing and midwifery researchers may consider using the Zelen design. However, legislation in 
some countries (for example, Australia and the UK) may make the Zelen design will be 
increasingly difficult to use. Nonetheless, the design may have applicability and utility in many 
settings and is worthy of consideration.  
There is clearly considerable controversy over the Zelen design within the literature. Controversy, 
nonetheless, is healthy and necessary. Dilemmas of this nature remain open for interpretation 
and continued debate is required between researchers who select and use such designs as 
Zelen’s and those who review and critique such studies. 
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Figure 1: The progression of participants in a conventional randomisation design. 
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Figure 3: The progression of participants using a double consent Zelen design. 
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